Introduction
A critical limitation in gene therapy protocols is the failure to restrict gene expression to the target tissue. This is of immense importance when considering suicide gene therapy strategies. A vast array of therapeutic regimens has been reported where transgenes are driven by a range of tissue or tumour specific, or alternatively, externally inducible promoters to achieve spatial and temporal control of gene expression. 1, 2 By far the most widely studied system utilizes radiation-inducible elements from the Early Growth Response (Egr-1) gene. Weichselbaum and co-workers 3, 4 have had much success using the CArG elements of the Egr-1 gene, reporting transcriptional control with both radiation and chemotherapeutic agents. TNFerade, a second-generation replication-deficient adenoviral vector carrying human tumour necrosis factor alpha under the control of this synthetic inducible promoter, has completed Phase I evaluation and has entered Phase II trials. 5, 6 We have also shown that a synthetic construct (pE9), incorporating nine radiosensitive CArG elements to drive inducible nitric oxide synthase (iNOS), was more effective than a constitutive CMV-driven construct both in vitro and in vivo. 7 The tumour microenvironment itself also presents opportunities to specifically target tumour tissue. Due to the ineffectual blood vessel network that exists in tumours, there are areas of low oxygen tension that are problematic for conventional cancer treatments in that they are inherently resistant to radio-or chemotherapy. 8 They can, however, be exploited by incorporating transcriptional transgene control, based on hypoxia responsive elements (HREs). An optimized hypoxia responsive promoter based on HREs from the hypoxia-inducible factor-1 (HIF-1) promoter achieved gene expression within the tumour comparable to that obtained with a CMV/IE promoter, whereas expression levels in liver and spleen were 1000-fold lower. 9 Furthermore, an adenovirus incorporating the HRE from the lactate dehydrogenase gene in a minimal SV40 promoter context was used to drive the prodrug activating gene, cytochrome P450 reductase, to increase the metabolism of the hypoxic cell radiosenstizer tirapazamine (TPZ). 10 Complete regression was achieved in a human tumour model (HT1080 fibrosarcoma), in which TPZ alone does not potentiate radiotherapeutic outcome.
Chimeric promoters have also been developed incorporating both hypoxia and radiation inducible elements. Both CArG elements and HREs, derived from the erythropoietin promoter, effectively controlled a suicide gene therapy strategy involving horseradish peroxidase and the prodrug indole-3-acetic acid. 11 Using HREs from the erythropoietin promoter ligated upstream from an Egr-TNF-a transgene construct, dual treatment with hypoxia and radiation resulted in 30% more TNF-a being produced than after either treatment individually. 12 Wild-type p53 Activated Fragment (WAF1/p21 WAF1/CIP1 herein referred to as WAF1) is a cyclin-dependent kinase inhibitor and a critical regulator of the cell cycle. It is controlled transcriptionally by p53-dependent and -independent mechanisms and post-translationally by the proteasome. 13, 14 The promoter region has a p53 binding site upstream of WAF1 coding sequences, which has been shown to confer p53-dependent inducibility. 15 However, it has also been demonstrated that a p53-independent activation pathway exists. 16 We have previously used the WAF1 promoter to drive expression of iNOS, resulting in modification of vascular tone in rat arteries ex vivo, and to achieve radiosensitization of tumour cells in vitro and in vivo. [17] [18] [19] The WAF1 promoter also restricted iNOS transgene expression to the radiation field. 19 Here, we further characterize the WAF1 promoter in a range of normal and human tumour cell lines of differing p53 status using a WAF1-driven green fluorescent protein (GFP) reporter construct. We show that induction by both radiation and hypoxia is independent of p53 status and that activation can be achieved by intracellularly concentrated radionuclides. Furthermore, we demonstrate that basal level activity of the WAF1 promoter is high in tumour cells, even without activation by radiation/hypoxia, but is low in normal cells, suggesting a further level of targeting specificity between normal and tumour cell lines. Significantly, we demonstrate radiosensitization in both p53 normal and mutant xenograft models using a clinically relevant gene therapy strategy incorporating WAF1/iNOS gene transfer in combination with a fractionated radiation regimen.
Results

Induction of the WAF1 promoter by radiation in the tumour cell lines
We have already shown that the WAF1 promoter was capable of driving GFP and iNOS in human endothelial cells, in rat tail arteries and in RIF1 tumour cells in vitro and in vivo in response to radiation. [17] [18] [19] Furthermore, we were able to show radiation inducibility in HT29 human colorectal tumour xenografts in vivo. 19 The present study aimed to determine both basal level activity and inducibility in a range of tumour cell lines. p53 has been shown to be important for the radiation-inducibility of p21, so we also wanted to determine the activity of this promoter in a range of cell lines with different p53 status in order to establish the appropriateness of this approach, particularly since 450% of human tumours have mutated p53. 16 The WAF1/pEGFP construct was therefore transfected into DU145 (p53 mutant), LNCaP (p53 wild type), HT29 (p53 mutant) and MCF-7 (p53 wild type) cells. At 24 h after transfection, these cells were exposed to 2, 4 and 6 Gy X-rays. The protein was extracted at 0-72 h after irradiation. The levels of GFP were determined by Western blotting and fold induction was calculated, following densitometric analysis of Western bands. Representative blots of radiationinduced GFP reporter activity in DU145 cells are shown in Figure 1a . In all tumour cell lines, GFP was expressed in the unirradiated time course indicating basal level WAF1 promoter activity in these cells (Figure 1b) . WAF1-mediated GFP expression was induced at all the radiation doses tested and in all cells, regardless of p53 status. At a clinically relevant 2 Gy dose of X-rays, GFP protein levels were higher than in non-irradiated controls in all the cell lines; however, only in DU145 and MCF-7 were they statistically significantly different (P ¼ 0.05 and 0.01 respectively for 24 h time point, analysis of variance (ANOVA)). Following a 4 Gy X-ray dose, protein levels were significantly higher than in non-irradiated controls for all the cell lines tested (P ¼ 0.04 for DU145; 0.015 for LNCaP; 0.006 for HT29; 0.02 for MCF-7 at the 8 h time point, ANOVA). At 48 h after 4 Gy X-rays, GFP protein levels were 6.3-fold greater than in unirradiated controls in DU145s, 3.6-fold greater in LNCaPs, 4.3-fold greater in HT29s and 3.4-fold greater in MCF-7s. The increase in WAF1-mediated GFP generally levelled off in all cells after 48 h.
Induction of the WAF1 promoter by hypoxia in tumour cell lines
A variety of very different signals can regulate the WAF1 promoter, and it therefore represents a unique sensor that is able to trigger transgene expression in response to a host of stress signals. 16 The results from HIF-1a null cells indicate that HIF-1a is required for hypoxia-induced upregulation of p21 (WAF1). Since hypoxia is a key environmental factor associated with solid tumours, we wanted to assess whether hypoxia could also trigger this promoter in tumour cells of differing p53 status.
The WAF1/pEGFP construct was transfected into DU145, LNCaP, HT29 and MCF-7 cells. At 24 h after transfection, these cells were exposed to 0.1% oxygen for 2 h. A further set of control cells was maintained in normal oxygenated conditions (95% air/5% CO 2 ). Protein was extracted from both treatment groups at 0-24 h with time 0 taken from the start of exposure to hypoxia. The levels of GFP were determined by Western blotting and fold induction was calculated. A representative blot showing hypoxia-induced GFP induction in DU145 cells is shown in Figure 2a . Under oxic conditions GFP was expressed in all cell lines, indicating basal level promoter activity (Figure 2b ). The WAF1 promoter was significantly induced after 2 h in 0.1% oxygen, with GFP protein levels being significantly higher than oxic controls for all cell lines (P ¼ 0.028 for DU145s; Po0.001 for LNCaPs; P ¼ 0.01 for HT29s; P ¼ 0.007 for MCF-7s for the 2 h time point, ANOVA). At 24 h after exposure to 2 h of hypoxia, levels of GFP were induced by 4.2-fold in DU145s; 2.89-fold in LNCaPs; 3.01-fold in HT29s and 3.20-fold in MCF-7s.
Expression of WAF1/GFP in normal cell lines
Since we had shown that the WAF1 promoter exhibited basal level expression in a range of human tumour cell Radiosensitization using targeted iNOS gene therapy HO McCarthy et al lines, we needed to assess basal level activity in a range of normal cell lines. This differential would be important for future studies where DNA constructs might be administered systemically to target metastatic disease. The WAF1/pEGFP construct was transfected into L132, FSK, HMEC (normal cells) and also into DU145 and LNCaP (tumour cells) for comparison within the same experiment. At 24 h after transfection, the protein was harvested and the levels of GFP determined by Western blotting (Figure 3 ). GFP expression was barely detectable in the three normal cell lines and yet high GFP levels were detected in the two tumour cell lines indicative of high basal level promoter activity. This increase in basal level activity in the tumour cell lines was not due to increased transfection efficiency, which was comparable between all cell lines tested (see Materials and methods). These data suggest that, not only is the WAF1 promoter inducible by radiation and hypoxia, it is also selectively inducible within a tumour cell environment by factors that have not yet been identified.
WAF1 promoter activity in SK-N-BE (2c) cells
We have also developed radio-targeted gene therapy approaches to localize radionuclides at tumour sites by inducing tumour cells to synthesize a membraneexpressed transporter. 20 The noradrenaline transporter (NAT) is responsible for uptake of the radionuclide, [ 211 At]meta-astatobenzylguanidine (MABG), appropriate for treatment of neuroblastomas. We wanted to test whether or not the WAF1 promoter could be activated by radionuclides so that in future studies it might be used with the NAT/MABG combination or indeed with other radionuclides in a brachytherapy approach. For this study, we used a neuroblastoma cell line, SK-N-BE, which was more appropriate than the tumour cell lines used for the external beam radiation experiments. The WAF1/pEGFP construct was transfected into SK-N-BE (2c) (p53 mutant) cells. At 48 h later, the cells were incubated with [ . As well as being activated by external beam radiation, these data demonstrate the feasibility of using WAF1 in studies to drive therapeutic transgenes in combination with radionuclides.
Growth delay of RIF-1 and HT29 tumours in vivo following fractionated WAF1/iNOS gene therapy and X-irradiation
We have shown that the WAF1 promoter is effective in driving the GFP reporter gene in both p53 wild type and Radiosensitization using targeted iNOS gene therapy HO McCarthy et al mutant cell lines in response to clinically relevant radiation doses. We have also shown previously that WAF1 could be used to drive iNOS expression in vivo and could sensitize both HT29 and RIF1 tumours to a single therapeutic radiation dose. 7, 18, 19 We also demonstrated that the iNOS levels were increased following direct injection of this construct into RIF1 tumours within 24 h with levels significantly elevated up to 5 days; similar results were seen with the HT29 xenograft, both before and after an inducing dose of radiation, to activate the WAF1 promoter. 18, 19 We now wanted to test this approach using fractionated radiation schedules in vivo at clinically relevant doses per fraction. Intradermal RIF-1 tumours were treated as described in Table 1 . Treatment efficacy was assessed by calculating the time taken for tumours to reach four times their treatment volume. Mean growth curves for each treatment are shown in Figure 5a with corresponding growth delay data in Table 2 . The control group, which received no treatment, reached four times its treatment volume in 10.7 days. Treatment with WAF1/iNOS alone (with no Treatment with WAF1/iNOS and fractionated X-rays gave a significant growth delay (P ¼ 0.05, ANOVA) of 8.871.08 days compared to treatment with empty vector and X-rays, which resulted in a 5.770.8 day regrowth delay (i.e. 50% greater). HT29 tumours were treated as described previously and treatment efficacy assessed by calculating the time taken to reach twice their treatment volume. Mean growth curves are shown in Figure 5b with corresponding growth delay data in Table 2 . No direct cytotoxicity was observed from WAF1/iNOS injection with or without priming dose, with growth delays not being significantly different from those obtained following injection with empty vector (P ¼ 0.44 with no priming dose and 0.6 with 4 Gy priming dose, ANOVA). However, treatment with WAF1/iNOS and fractionated X-rays resulted in a highly significant (P ¼ 0.0004, ANOVA) tumour regrowth delay of 12.771.25 days compared to the 8.470.85 days obtained with empty vector and fractionated X-ray treatment (i.e. 50% greater). Increased iNOS levels were found in HT29 tumours injected with the WAF1/iNos construct.
Discussion
Radiotherapy can be delivered both externally (mainly by X-rays) or internally with the use of radionuclides, and remains one of the main strategies for treating most forms of solid tumour. Several approaches are now being developed to improve local tumour control without compromising normal tissues. Recent advances in conformal and intensity-modulated radiation therapy have resulted in more efficient targeting and precision of dose deposition to the tumour volume. The innovative marriage of radiation with gene therapy, termed radiogenic therapy, has been used to enhance antitumour efficacy and clinical trials combining these two modalities are now under way. 21 Gene therapy vectors that incorporate radiation-inducible promoters, thus allowing controlled expression of the therapeutic gene following irradiation, have been generated and the approach has been successfully demonstrated in animal models. 22 Delivery of such vectors to the tumour allows temporal and spatial expression of the transgenes within the radiation field. Hypoxia is a physiological characteristic of solid tumours, which can reduce the effectiveness of both radio-and chemo-therapy. 23 Nevertheless, hypoxia has also been exploited to drive therapeutic gene expression from gene therapy vectors delivered to solid tumours exhibiting significant areas of low oxygen tension.
We have already reported that transcriptional targeting using the WAF1 promoter is very effective; restricted and enhanced transgene protein levels were observed only in tissue within the radiation field, even though vector sequences were detected in all the main organs tested. 19 Furthermore, we have previously shown that WAF1 driving the therapeutic transgene, iNOS, is a successful strategy, leading to tumour cell radiosensitization in vitro and delayed tumour regrowth in vivo using large single doses of X-rays; 18, 19 intra-tumoral injection of WAF1/iNOS combined with a priming dose of X-rays to induce the WAF1 promoter, followed by a treatment dose, resulted in sensitizer enhancement ratios (SERs) of B2.0 and B1.6 in RIF-1 and HT29 tumours, respectively, compared with radiation treatment alone. Figure 5 Tumour growth delay following WAF1/iNOS gene therapy in combination with fractionated irradiation in the RIF-1 (a) and HT29 (b) tumour models. The WAF1/iNOS transgene was injected intratumorally using the TransIT liposome delivery agent and 24 h later the tumours were treated with fractionated radiotherapy based on a 6-day schedule as described in Table 1 . Tumours were measured until they reached four times (RIF-1) or two times (HT29) their treatment volume.
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In the present study, we aimed to determine if the p53 status of a tumour cell line was important for WAF1 inducibility by radiation and hypoxia and also to assess basal level activity of the WAF1 promoter in a variety of normal cell lines. We have been able to show that p53 status was not important for inducibility both by radiation and by hypoxia; in all cell lines tested a 4 Gy dose of X-rays resulted in a 3.6-to 6.3-fold increase in GFP reporter expression 48 h after irradiation. Although most studies suggest that p53 is required for the radiation inducibility of WAF1, there is a plethora of evidence to suggest WAF1 can be activated independently of p53. 16 Furthermore, there is a p53 and apoptosis-independent role for p21 (WAF1) in tumour response to radiation therapy, which is consistent with our data. 24, 25 We were also able to demonstrate that following exposure to hypoxia, all cell lines, independent of p53 status, had three-to five-fold higher levels of GFP than normoxic cells. These data are consistent with our previous study in the HT29 cell line. 19 These data may be explained by the observation that p21 (WAF1) activation by the hypoxia inducible factor, HIF-1a, occurs by a novel mechanism involving the displacement of Myc binding from the p21 (WAF1) promoter by the HIF-1a PAS domain. 26 This HIF-1a-Myc pathway may account for regulation of hypoxia-responsive genes that lack an HRE. 26, 27 Furthermore, these authors suggest that p53 is not absolutely required for hypoxia-induced p21 (WAF1) activation (unpublished data) and this is in agreement with previous reports. 28, 29 Our data suggest that the WAF1 promoter is a good candidate for use in targeted cancer gene therapy for tumours where p53 is mutated (in 450% of all tumours) and is often associated with resistance to radiotherapy. 30, 31 The data presented in this paper also show that basal level activity from the WAF1 promoter was increased even in the absence of an inducer such as radiation or hypoxia. This lead us to question whether the basal activity might also be increased in normal cells, which would obviously limit the applicability of this promoter following systemic delivery. Fortunately, basal level activity was virtually undetectable in all three normal cell lines used, in contrast with the DU145 and LNCaP tumour cell lines tested under identical conditions and with comparable transfection efficiencies. Published data help to explain the observed increase in basal level activity in tumours compared to normal cells. Firstly, it has been widely reported that p21 (WAF1) is upregulated in a variety of tumour types including colorectal, ovarian and oral squamous cell carcinomas. [32] [33] [34] Furthermore, it has been shown that loss of topological control of p21 (WAF1) is one of the earliest features of malignancy in the colorectal system. 35 Finally, p21 (WAF1) can also function as an antiapoptotic and growth promoting protein under certain conditions. [36] [37] [38] Our data suggest, therefore, that WAF1 can be described as a tumour specific promoter in well-oxygenated conditions, a hypoxia responsive promoter and a radiation inducible promoter.
While we have shown that basal level activity of the WAF1 promoter was absent in normal cell lines, we have also demonstrated that WAF1 is radiation inducible in 'normal' HMEC-1 and in ex vivo rat tail artery preparations. 17 However, in a clinical setting, the use of conformal radiotherapy for maximum targeting of the tumour tissue, should minimize gene activation in normal tissues. Indeed, we see very minimal activation at 2 Gy and the dose to most normal tissues would certainly fall far below this level. Furthermore, if the transgene were delivered directly to the tumour, very little construct should reach normal tissues. As for hypoxia inducibility, this would be negligible in normal tissues, which are generally well oxygenated. In a clinical setting our strategy should therefore be effective.
We have also demonstrated that, as well as being inducible by external beam radiation, WAF1 is inducible by targeted delivery of radionuclides. The treatment of SK-N-BE(2c) neuroblastoma cells with graded concentrations of [ 211 At]MABG increased the expression of the GFP reporter gene in a dose-and time-dependent manner. We intend to determine the most efficient type of radiation trigger by comparing the potency of alternative radiohaloanalogues of benzylguanidine. Thereby, we will establish the most favourable conditions for upregulating the expression of therapeutic transgenes in neuroblastoma cells.
Taken together, these characteristics make the WAF1 promoter highly attractive for use in gene therapy using either direct tumour injection or systemic delivery (when this becomes available) to target metastatic deposits where tumour and hypoxia specific expression of toxic transgene products would be attainable.
A vast number of promoters for gene therapy, which can be transcriptionally controlled by either X-rays or hypoxia, have been reported. 1 However, only a few promoter systems incorporating both these elements have been utilized. Most recently Wang et al. 39 successfully used a synthetic construct using HREs upstream of the Egr-1 promoter to control expression of HSV-TK in A549 lung adenocarcinoma xenografts. The same laboratory also delivered oncostatin M using the same model system and found that a radiation dose of 6 Gy or hypoxia markedly induced transgene expression. 39 In the final part of this study, we wanted to evaluate the ability of WAF1 to activate iNOS, delivered with a clinically relevant fractioned radiotherapy regimen. The effectiveness of iNOS gene therapy as an anticancer treatment has been well documented, with reports that it suppresses tumourigenicity and metastatic potential in vitro and results in effective growth inhibition in vivo. 40, 41 We were the first group to report on the use of iNOS gene Radiosensitization using targeted iNOS gene therapy HO McCarthy et al therapy to radiosensitize rodent and human tumour xenografts in vivo. 18, 19 In these studies, we also demonstrated that NO K was generated in vivo following injection of both CMV-driven iNOS and WAF-driven iNOS and that this effect could be inhibited in vitro using the NOS inhibitor L-NAME. More recently Cook et al. 42 used a combination of adenovirus-delivered iNOS and a fractionated radiation regimen, which resulted in a significant tumour growth delay via apoptosis in a colorectal tumour model. We have now extended these studies by using a non-viral approach together with transcriptional targeting and a fractionated approach which is clinically relevant.
In the present study, injection of the WAF1/iNOS construct, without a priming dose of radiation, into the RIF-1 tumour model, resulted in a slight but significant growth delay of 1.871 days. This can be attributed to the fact that RIF-1 cells have wild-type p53, which seems essential for proapoptotic effects of NO K42,43 ; in the p53 mutant HT29 model, we observed no direct cytotoxicity. This confirms our previous data using single doses of radiation. 19 Radiation regimens using multiple small doses of radiation are the ultimate and most challenging test for any therapeutic strategy that aims to radiosensitize hypoxic cells. This is because reoxygenation almost certainly occurs between fractions, reducing the impact of hypoxia resistance so that the maximum SER achievable is necessarily reduced. In the present study, the SERs we obtained (1.42 and 1.6 in the RIF-1 and HT29 models respectively) even though the hypoxic cell fraction will have been diminished over the 1 week of treatment. The fact that we showed statistically significant responses suggests that fractionated radiation schedules on their own are not sufficient to eliminate all the hypoxic cells and therefore some tumours would benefit from such a gene therapy approach. In reality, the enhancement of tumour growth inhibition we observed could potentially be significant in the clinical setting in combination with fractionated radiotherapy. This is supported by the work of Cook et al., 42 who demonstrated that although the synergistic effect of NO K and ionizing radiation occurred via activation of p53 by phosphorylation at serine 15, p53-independent pathways also exist.
Although our gene therapy protocols achieved clinically relevant and potentially important anticancer effects, they are not yet fully optimized. For example, ionizing radiation has been reported to increase gene uptake in vitro and in vivo. 44, 45 In our fractionated schedule, we administered the gene therapy on day 1, with radiation treatment beginning on day 2, it may be advisable in light of these findings, to include a 2 Gy radiation dose prior to gene therapy. In addition, more frequent administration of iNOS gene therapy has been shown to be beneficial. 39 In conclusion, these studies demonstrate that the WAF1 promoter has highly desirable characteristics for use in transcriptionally targeted cancer gene therapy since it is essentially silent in normal well-oxygenated cells, but appears to have significant basal level expression in tumour cells. In addition, the promoter can be further induced by elements of the tumour microenvironment (hypoxia) and routinely used therapy (radiation/radionuclides). Finally, WAF1/iNOS gene therapy is effective in radiosensitizing both p53-wild type and mutant tumours in a clinically relevant schedule.
Materials and methods
Maintenance of cells in vitro
All cell culture reagents were obtained from Invitrogen, (Paisley, UK) unless otherwise stated. Human prostate carcinoma cells DU145 and LNCaP (obtained from Cancer Research UK [CRUK] ) and the murine RIF-1 fibrosarcoma cell-line (a kind gift from Professor JM Brown, Stanford University, USA) were grown as monolayers in RPMI 1640 supplemented with 10% foetal calf serum (FCS; Globepharm, address UK). Human HT29 colon cancer cells, MCF-7 breast carcinoma cells (CRUK) and the normal cell lines, human microvascular endothelial cells (HMEC-1) (a kind gift from Dr E Ades, Centre for Disease Control, Atlanta, GA, USA), lung epithelial (L132) (American Tissue Culture Collection (ATCC)) and human foreskin (FSK) (CRUK) were grown as monolayers in minimal essential medium supplemented with 10% FCS (Globepharm, UK). Human neuroblastoma SK-N-BE(2c) cells (a kind gift from Paolo Montaldo, Gaslini Institute, Genova) were maintained in RPMI-1640 medium supplemented with 10% heatinactivated foetal bovine serum, 50 IU/ml sodium penicillin G, 50 mg/ml streptomycin sulphate and 2 mM L-glutamine. All cells were grown at 371C under 5% CO 2 /95% air, and passaged every 3-4 days to maintain exponential growth.
Implantation of tumours in vivo
RIF-1 tumours for in vivo experiments were obtained by intradermal injection of 2 Â 10 5 cells (in a volume of 0.05 ml. phosphate-buffered saline (PBS)) on the rear dorsum of lightly anaesthetized (isofluorane inhalation) 10-12-week-old female C3H mice. HT29 tumours for in vivo experiments were obtained by intradermal injection of 1 Â 10 7 cells (in a volume of 0.1 ml PBS) on the rear dorsum of lightly anaesthetized (isofluorane inhalation) 8-12 weeks old Balb-C SCID mice. Mice were treated when tumours reached a volume of 150-250 mm 3 . All animal experiments were carried out in accordance with the Animal (Scientific Procedures) Act 1986 and conformed to the current UKCCCR guidelines.
Vector construction WAF1/pEGFP reporter vector. The WAF1 (2.4 kb) promoter (a kind gift from Professor B Vogelstein, John Hopkins Oncology Centre, Baltimore, USA) was cloned into the Xho1 site of the pEGFP-1 reporter vector (BD Biosciences, Oxford, UK).
WAF1/iNOS vector. GFP was removed from the WAF1/pEGFP vector as described previously 17 using Kpn1 and Not1 restriction enzymes (Invitrogen, Paisley, UK). iNOS was excised from the original construct (a kind gift from Professor T Billiar, School of Medicine, Pittsburgh, USA) and directionally cloned into the Kpn1-Not1 sites of the WAF1 vector after removal of EGFP.
In vitro transfections
All cells for transfection were treated using the same procedure. 1 Â 10 5 cells were seeded into 35 mm Petri 
Cell irradiation experiments
At 24 h after transfection, cells were irradiated with 0, 2, 4 or 6 Gy X-rays using a Pantak X-ray machine (Pantak, Reading, UK) operated at 250 kV (dose rate: 1.17 Gy/ min). At various time points after irradiation, cells were washed several times with PBS and then harvested for protein analysis.
Hypoxia experiments
At 24 h after transfection, cells were placed in a 0.1% O 2 atmosphere within a hypoxic workstation (Ruskinn, Biotrace, Wales, UK) at 371C for 2 h. At various time points during and after hypoxia, the cells were washed with PBS and then harvested for protein analysis. 
Western blotting
Protein concentration was measured using UV spectrometry. Each sample (30 mg) was electrophoresed through a 1% sodium dodecyl sulfate (SDS)-polyacrylamide gel, transferred onto a nitrocellulose membrane (Hybond-C, Amersham, UK) and probed with a mouse monoclonal anti-GFP antibody at 1:1000 (BD Biosciences, Oxford, UK). Levels of gene expression were assessed using an ECL detection kit with Kodak Analysis Software to assess the intensity of each band on the autoradiograph. Three independent experiments were carried out and the mean results reported7standard error (s.e.) after correction with either a b-actin or GAPDH loading control.
In vivo tumour growth delay assay
When tumours reached the appropriate treatment size (150-250 mm 3 ), animals were randomly allocated to treatment groups -Controls: no treatment; fractionated radiation regimen only; priming X-ray dose only (4 Gy, previously ascertained as optimal priming dose vector only gene therapy) WAF1/iNOS gene therapy alone (all groups n ¼ 3 for HT29; 5 or more for RIF-1). 17 Combination gene therapy and X-ray treatment -Vector gene therapy and priming X-ray dose only, vector gene therapy and fractionated X-ray regimen, WAF1/iNOS gene therapy and priming X-ray dose, WAF1/iNOS gene therapy and fractionated X-ray regimen (all groups n ¼ 4 for HT49; 5 or more for RIF-1). Further details of treatment protocols for all groups are shown in Table 1 .
Gene therapy was administered by direct intratumoral injection of 25 mg of appropriate DNA using a TransIT in vivo transfection kit (Mirus, Cambridge Bioscience, Cambridge, UK). After 24 h and immediately prior to each radiation dose, all mice (including controls, regardless of other treatments) were injected i.p. with 200 ml of 10 À3 M tetrahydrobiopterin (BH 4 , an essential iNOS co-factor), then placed in lead jigs to shield the body of the animal with the exception of the tumour. The tumours were then irradiated in air with X-rays (250 kVp; 0.85 Gy/min). During the fractionated X-ray regimen, a gap of 6 h was maintained between the two daily radiation treatments. Tumours were measured daily until day 7, then every 2 days until the tumour reached four times its treatment size for RIF-1, or two times treatment size for HT29. The animal was then killed. Growth curves were plotted for each group and growth delays calculated for each treatment relative to the control group.
